Displaying all 4 publications

Abstract:
Sort:
  1. Ransing R, Vadivel R, Halabi SE, Jatchavala C, Shalbafan M, Noël C, et al.
    Indian J Psychol Med, 2023 Jan;45(1):65-68.
    PMID: 36778626 DOI: 10.1177/02537176211052071
  2. Ransing R, Koh EBY, Ramalho R, de Filippis R, Pinto da Costa M, Pereira-Sanchez V, et al.
    Front Psychiatry, 2023;14:1230059.
    PMID: 37692313 DOI: 10.3389/fpsyt.2023.1230059
  3. Stowe MJ, Calvey T, Scheibein F, Arya S, Saad NA, Shirasaka T, et al.
    J Addict Med, 2020 12;14(6):e287-e289.
    PMID: 33009167 DOI: 10.1097/ADM.0000000000000753
    : Globally, there are concerns about access to healthcare and harm reduction services for people who use drugs (PWUD) during the coronavirus disease 2019 (COVID-19) pandemic. Members from the Network of Early Career Professionals working in Addiction Medicine shared their experiences of providing treatment to PWUD during the COVID-19 pandemic. Drawing on these qualitative reports, we highlight the similarities and discrepancies in access to services for PWUD in 16 countries under COVID-10 restrictions. In most countries reported here, efforts have been made to ensure continued access to services, such as mobilising opioid agonist maintenance treatment and other essential medicines to patients. However, due to travel restrictions and limited telemedicine services, several Network of Early Career Professionals working in Addiction Medicine members from lower-resourced countries experienced challenges with providing care to their patients during periods of COVID-19 lock-down. The insights provided in this commentary illustrate how the COVID-19 lock-down restrictions have impacted access to services for PWUD.
  4. Scheibein F, Stowe MJ, Arya S, Morgan N, Shirasaka T, Grandinetti P, et al.
    Front Psychiatry, 2021;12:634309.
    PMID: 33796034 DOI: 10.3389/fpsyt.2021.634309
Related Terms
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links